Brief: Mirati Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Corporate Updates
28/02/2023 22:20
Feb 28 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND RECENT CORPORATE UPDATES
* CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF
APPROXIMATELY $1.1 BILLION AS OF DECEMBER 31, 2022
* QTRLY LOSS PER SHARE $3.51
* Q4 EARNINGS PER SHARE VIEW $-3.55 -- REFINITIV IBES DATA
Source text for Eikon: ID:nPn6P2TDwa
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)